(Received for publication May 9, 1985) 3,3"-Di-O-acyl-4"-O-sulfonyl and 3,3"-di-O-acyl-4"-O-alkyl derivatives of spiramycin I were synthesized and evaluated by four parameters, antibacterial activity, affinity to ribosomes, lypophilicity and therapeutic effects. Among them, 3,3"-di-O-acetyl-4"-O-mesyl and 3,3"-di-O-acetyl-4"-O-methylspiramycin I having relatively small substituents at 4"-position were the most effective in mouse protection tests, and the results were comparable to acetylspiramycin.
In a previous paper1), we reported that 4"-sulfonates and 4"-alkylethers of spiramycin I, which were estimated to delay metabolism of spiramycin in the body, showed superior in vitro activities and were almost comparable to spiramycin I in vivo. In another paper2), we also described that some of the 3,3",4"-triacyl derivatives of spiramycin I were more effective in vivo than acetylspiramycin. From these findings, we have been very interested in the synthesis and activities of the 3,3"-diacylates of 4"-O-sulfonyl and 4"-O-alkylspiramycin I. Details of the synthesis and activities of the derivatives are described in this paper. acetall3 were used as starting materials bearing a free hydroxyl group at 3"-position. However, acylation of 3"-hydroxyl group of 2'-O-acetyl-4"-O-mesylspiramycin I 3,18-O-(tert-butyldimethylsilyl)acetal (1) did not occur even under severe conditions because of hindrance from the tert-butyldimethylsilyl (TBDMS) protective group2). The TBDMS group of 1 was removed by treatment with tetrabutylammonium fluoride to give 2'-O-acetyl-4"-O-mesylspiramycin I (2). On the treatment of 2 with acetic anhydride and dirnethylaminopyridine in CHCl3 at refluxing temperature, similar to the conditions used for synthesis of 3,3",4"-tri-O-acylspiramycin I2), the desired 3"-acylate was not obtained. We therefore applied more drastic conditions which have been utilized for the preparation of 3"-acylleucomycin
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Treatment of 2 with acetyl chloride in the presence of tribenzylamine in 1,2-dichloroethane at refluxing temperature gave predominantly 3,18,2',3"-tetra-O-acetyl-17,18-enol-4"-O-mesylspiramycin I (3) and a small amount of 3,2',3"-tri-O-acetyl-4"-O-mesylspiramycin I (4) 4, . d 38.9 (SCH3); 21. 2, 22.4, . e 8. 3, 46.4 (SCH2CH3); 21.2, 22.4, .
f 12.9, 17.3, 53.5 (SCH2CH2CH3); 21.3, 22.4, . g 8 . 2, 46.4 (SCH2CH3); 9.0, 27.7, 9.2, 28.8, . h 62 .2 (CH3); 21. 3, 22.3, . i 15.7, 69.8 (CH2CH3); 21. 3, 22.4, . l 10. 5, 23.5, 76.1 (CH2CH2CH3); 9.0, 27.7, 9.2, 28.7, . Table 3 . MIC, ID50, survival % and retention time in HPLC (RT) of 3,3"-diacylates of 4"-O-sulfonyl and 4"-O-alkylspiramycin I. The structure of 5 was confirmed by 13C NMR (Table 1 ) and mass spectral evidence ( Table 2 ).
The 13C NMR spectrum of 5 showed signals of two acetyl and one mesyl group, downfield shifts of 3-and 3"-carbons and upfield shifts of 1-, 18-, 2"-, 5"-and 7"-carbons compared with that of 4"-Omesylspiramycin I, indicating that 3-and 3"-hydroxyl groups of 4"-O-mesylspiramycin I were acetylated. The mass spectral fragmentation (Table 2 ) also assisted this structure. The structures of 11 ~ 16 were also confirmed in the similar manner.
The chemical shifts of acyl carbons of all the derivatives agreed with the experimental rule between the bonding positions and the 13C NMR chemical shifts of acyl groups in spiramycins2).
Evaluation by Antibacterial Activity, Affinity to Ribosomes, Lipophilicity and Therapeutic Effect Spiramycin I derivatives prepared as described above were evaluated by four parameters; in vitro antibacterial activity (MIC), affinity to ribosomes (ID50)4), lipophilicity (retention time in HPLC5 )) and therapeutic effect in mice (survival %), as shown in Table 3 . In in vitro antibacterial activity, 3,3"-di-O-acyl derivatives of 4"-O-sulfonylspiramycin I were comparable to spiramycin I but 4"-alkylethers showed considerably lower activity. Almost all the derivatives showed affinity to ribosomes comparable to or somewhat weaker than acetylspiramycin. A relationship between ribosome affinity and antibacterial activity was not found. Experimental NMR spectra were measured on a Jeol FX-100 spectrometer in CDCI3 solution. Mass spectra were obtained on a Jeol D-100 and DX-300 spectrometer at 20 eV. Optical rotations were measured with a Jasco DIP-181 polarimeter. UV spectra were taken with a Shimadzu UV-210A spectrometer. Thin-layer chromatography (TLC) was performed on pre-coated plates, Merck Kieselgel 60 F254 with CHCl3 -MeOH -conc NH4OH, 10: 1: 0.01. Silica gel column chromatography was performed with Merck Kieselgel 60.
MIC Determination
The MIC values of each derivative against various bacteria were determined by the agar dilution method using heart infusion agar (pH 7.0).
ID50 for the Binding to Ribosomes
The 50% inhibition doses (ID50) of the derivatives for [10,11,12,13-3H] tetrahydroleucomycin A3 binding to Escherichia coli ribosomes were determined as described previously4).
Retention Time (RT) in HPLC HPLC was performed on a reverse phase silica gel column (Merck Lichrosorb RP-8, 4 x 250 mm) with CH3CN -0.2 M NaH2PO4, 1: 2, as a solvent system5). RT was recorded at 1 ml/minute of flow rate with a UV monitor (231 nm).
Therapeutic Effect in Experimental Mice Protection Test
The therapeutic effect was represented by survival percent. Mice (ddY; o : 19=1 g, 10 mice per a group) were infected intraperitoneally with Streptococcus pneumoniae Type III. Compounds suspended in 0.3 % sodium carboxymethyl cellulose were administered po immediately after infection. The survival percent values were recorded as percentages of the survival mice on the doses 100, 60 and 40 mg/kg at 7 day after infection. -4"-O-mesylspiramycin I 3,18-0-(tent-butyldimethylsilyl) acetal (1)1) (1.42 g) was dissolved in I M solution of tetrabutylammonium fluoride in THE (1.58 ml) and stood for 1.3 hours at room temp. The reaction mixture was diluted with CHCl3 (140 ml), washed with H2O (140 ml), dried over Na2SO4, and evaporated to give an oily residue, which was chromatographed on a silica gel column with C6H6 -Me2CO To an ice-cooled solution of 2 (200 mg) in 1,2-dichloroethane (0.8 ml), tribenzylamine (632 mg) and acetyl chloride (0.16 ml) were mixed and heated at 75°C for 2 days. After addition of MeOH, the reaction mixture was diluted with CHCl3 (20 ml) and washed with a NaHCO3-saturated solution (20 ml) and then H2O (20 ml). The CHCl3 layer was dried over Na2SO4 and evaporated to give a residue, which was chromatographed on a silica gel column with C6H6 -Me2CO, 5: 1, to give 3 and 4 in the order of elution, as colorless powders. To an ice-cooled solution of 2 (850 mg) in 1,2-dichloroethane (3.4 ml), tribenzylamine (2.69 g) and acetyl chloride (0.68 ml) were mixed and heated at 80°C for 2 days. After addition of MeOH, the reaction mixture was diluted with CHCl3 (85 ml) and washed with a NaHCO3-saturated solution (85 ml) and then H2O (85 ml). The CHCl3 layer was dried over Na2SO4 and evaporated to give a residue. The residue was dissolved in 70% MeOH (48 ml) and heated at 50°C for 22 hours. The reaction mixture was diluted with CHCl3 (85 ml) and washed with a NaHCO3-saturated solution (85 ml). The CHCl3 layer was dried over Na2SO4 and evaporated to give a colorless solid, which was chromatographed on a silica gel column with C6H6 -Me2CO 
